^
    11h
    A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2/3 trial
    |
    azacitidine
    16h
    Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, CStone Pharmaceuticals | Trial completion date: Jun 2029 --> Dec 2029 | Trial primary completion date: Jun 2028 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • oxaliplatin • Cejemly (sugemalimab) • Oncaspar liquid (pegaspargase)
    20h
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    azacitidine
    3d
    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 30
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    4d
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    5d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    6d
    ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)
    The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Rituxan (rituximab) • carmustine
    6d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    6d
    Clinical Study on the Efficacy and Safety of Zeprumetostat, Azacitidine Combined with Lipo-MIT in Relapsed/Refractory Peripheral T-Cell Lymphoma. (ChiCTR2600116686)
    P2, N=26, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • zeprumetostat (SHR-2554) • Duoenda (mitoxantrone liposomal)
    6d
    A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)
    P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
    6d
    ZG005 combination hydrochloride gilteritinib tablets in patients with relapsed or refractory lymphoma: a multicentre, open-label, dose-exploration and dose-expansion phase I/II clinical study. (ChiCTR2500114728)
    P1/2, N=60, Recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P1/2 trial
    |
    Xospata (gilteritinib) • giredestrant (RG6171) • nilvanstomig (ZG005) • ravoxertinib (RG7842)
    7d
    Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    TNFRSF8 positive
    |
    lenalidomide • dexamethasone • Istodax (romidepsin) • Onureg (azacitidine oral)